Showing results (381-390 of 412) with videos related to

Sort By:
Pageof 42
The Journal of Clinical Investigation|November 15, 2023
LAIR-1 agonism as a therapy for acute myeloid leukemiaRustin R Lovewell, Junshik Hong, Subhadip Kundu, et al.
Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Journal of Public Health Management and Practice : JPHMP|September 22, 2023
Ohio Coronavirus Wastewater Monitoring Network: Implementation of Statewide Monitoring for Protecting Public HealthZuzana Bohrerova, Nichole E Brinkman, Ritu Chakravarti, et al.
Cancers|January 30, 2021
GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future DirectionsRiccardo Di Fiore, Sherif Suleiman, Bridget Ellul, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2023
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with MyelofibrosisTamara K Moyo, Ashwin Kishtagari, Matthew T Villaume, et al.
The Journal of Clinical Investigation|November 18, 2025
Clonal hematopoiesis activates procalcific pathways in macrophages and promotes aortic valve stenosisWesley T Abplanalp, Michael A Raddatz, Bianca Schuhmacher, et al.
The Lancet. Haematology|December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 studyGuillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Cancer Discovery|January 25, 2020
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Daniel A Pollyea, Annika Gustafson, et al.
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Pageof 42